{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:26:25Z","timestamp":1793039185773,"version":"4.5.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11010-021-04325-9","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T19:03:06Z","timestamp":1641841386000},"page":"711-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features"],"prefix":"10.1007","volume":"477","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-170X","authenticated-orcid":false,"given":"Foad","family":"Rommasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3279-0671","authenticated-orcid":false,"given":"Mohammad Javad","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-8442","authenticated-orcid":false,"given":"Mehdi","family":"Mirsaeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"issue":"3","key":"4325_CR1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","volume":"25","author":"TP Velavan","year":"2020","unstructured":"Velavan TP, Meyer CG (2020) The COVID-19 epidemic. Trop Med Int Health 25(3):278","journal-title":"Trop Med Int Health"},{"issue":"7798","key":"4325_CR2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270\u2013273","journal-title":"Nature"},{"key":"4325_CR3","doi-asserted-by":"publisher","DOI":"10.9734\/jammr\/2020\/v32i430393","author":"SS Ahmed","year":"2020","unstructured":"Ahmed SS (2020) The Coronavirus disease 2019 (COVID-19): a review. J Adv Med Medl Res. https:\/\/doi.org\/10.9734\/jammr\/2020\/v32i430393","journal-title":"J Adv Med Medl Res"},{"issue":"2","key":"4325_CR4","first-page":"11","volume":"34","author":"E Toniato","year":"2020","unstructured":"Toniato E, Ross R, Kritas S (2020) How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents 34(2):11\u201316","journal-title":"J Biol Regul Homeost Agents"},{"key":"4325_CR5","first-page":"339","volume":"34","author":"P Conti","year":"2020","unstructured":"Conti P, Younes A (2020) Coronavirus COV-19\/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 34:339","journal-title":"J Biol Regul Homeost Agents"},{"key":"4325_CR6","volume-title":"The coronavirus disease 2019 (COVID-19)","author":"JR Hageman","year":"2020","unstructured":"Hageman JR (2020) The coronavirus disease 2019 (COVID-19). SLACK Incorporated, Thorofare, NJ"},{"issue":"14","key":"4325_CR7","first-page":"7816","volume":"24","author":"PA Pashaki","year":"2020","unstructured":"Pashaki PA, Roudkenar MH, Rahim F, Ebrahimi A (2020) From SARS-CoV to SARS-CoV2: a potential guide to better understanding of pathophysiology of the disease and potential therapeutic modality. Eur Rev Med Pharmacol Sci 24(14):7816","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"4325_CR8","doi-asserted-by":"crossref","first-page":"e9610","DOI":"10.15252\/msb.20209610","volume":"16","author":"F Hikmet","year":"2020","unstructured":"Hikmet F, M\u00e9ar L, Edvinsson \u00c5, Micke P, Uhl\u00e9n M, Lindskog C (2020) The protein expression profile of ACE2 in human tissues. Mol Syst Biol 16(7):e9610","journal-title":"Mol Syst Biol"},{"key":"4325_CR9","first-page":"9180","volume":"71","author":"C Fan","year":"2020","unstructured":"Fan C, Li K, Ding Y, Lu WL, Wang J (2020) ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. MedRxiv 71:9180","journal-title":"MedRxiv"},{"key":"4325_CR10","doi-asserted-by":"crossref","first-page":"110267","DOI":"10.1016\/j.biopha.2020.110267","volume":"128","author":"R Salvi","year":"2020","unstructured":"Salvi R, Patankar P (2020) Emerging pharmacotherapies for COVID-19. Biomed Pharmacother 128:110267","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"4325_CR11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W-J Guan","year":"2020","unstructured":"Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DS (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708\u20131720","journal-title":"N Engl J Med"},{"issue":"7","key":"4325_CR12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(20)30229-0","volume":"8","author":"C Ronco","year":"2020","unstructured":"Ronco C, Reis T, Husain-Syed F (2020) Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 8(7):738\u2013742","journal-title":"Lancet Respir Med"},{"issue":"4","key":"4325_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424\u2013432","journal-title":"J Med Virol"},{"key":"4325_CR14","first-page":"43","volume":"12","author":"I Guizani","year":"2021","unstructured":"Guizani I, Fourti N, Zidi W, Feki M, Allal-Elasmi M (2021) SARS-CoV-2 and pathological matrix remodeling mediators. Inflamm Res 12:43","journal-title":"Inflamm Res"},{"issue":"1","key":"4325_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00011-020-01413-2","volume":"70","author":"S Toldo","year":"2021","unstructured":"Toldo S, Bussani R, Nuzzi V, Bonaventura A, Mauro AG, Cannat\u00e0 A, Pillappa R, Sinagra G, Nana-Sinkam P, Sime P (2021) Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res 70(1):7\u201310","journal-title":"Inflamm Res"},{"issue":"5","key":"4325_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/v4050833","volume":"4","author":"TE Cecere","year":"2012","unstructured":"Cecere TE, Todd SM, LeRoith T (2012) Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses 4(5):833\u2013846","journal-title":"Viruses"},{"issue":"7\u20138","key":"4325_CR17","first-page":"370","volume":"73","author":"Q Maloir","year":"2018","unstructured":"Maloir Q, Ghysen K, Von Frenckell C, Louis R, Guiot J (2018) Acute respiratory distress revealing antisynthetase syndrome. Rev Med Liege 73(7\u20138):370\u2013375","journal-title":"Rev Med Liege"},{"issue":"6","key":"4325_CR18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","volume":"7","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H (2020) Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev 7(6):998\u20131002","journal-title":"Natl Sci Rev"},{"issue":"1","key":"4325_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03062-7","volume":"24","author":"S Pons","year":"2020","unstructured":"Pons S, Fodil S, Azoulay E, Zafrani L (2020) The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 24(1):1\u20138","journal-title":"Crit Care"},{"key":"4325_CR20","doi-asserted-by":"crossref","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","volume":"218","author":"S Yeleswaram","year":"2020","unstructured":"Yeleswaram S, Smith P, Burn T, Covington M, Juvekar A, Li Y, Squier P, Langmuir P (2020) Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clin Immunol 218:108517","journal-title":"Clin Immunol"},{"key":"4325_CR21","doi-asserted-by":"crossref","first-page":"106924","DOI":"10.1016\/j.intimp.2020.106924","volume":"88","author":"H Owji","year":"2020","unstructured":"Owji H, Negahdaripour M, Hajighahramani N (2020) Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol 88:106924","journal-title":"Int Immunopharmacol"},{"key":"4325_CR22","volume-title":"Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports","author":"E Mahase","year":"2021","unstructured":"Mahase E (2021) Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. British Medical Journal Publishing Group, London"},{"issue":"11","key":"4325_CR23","first-page":"4163","volume":"25","author":"F Rommasi","year":"2021","unstructured":"Rommasi F, Nasiri M, Mirsaiedi M (2021) Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data. Eur Rev Med Pharmacol Sci 25(11):4163\u20134173","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"4325_CR24","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.clinthera.2004.12.019","volume":"26","author":"DE Furst","year":"2004","unstructured":"Furst DE (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26(12):1960\u20131975","journal-title":"Clin Ther"},{"key":"4325_CR25","first-page":"229","volume-title":"Treatment of rheumatoid arthritis with IL-1 inhibitors","author":"C Gabay","year":"1998","unstructured":"Gabay C, Arend WP (1998) Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer, Berlin, pp 229\u2013246"},{"key":"4325_CR26","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","volume":"11","author":"D Ragab","year":"2020","unstructured":"Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol 11:1446","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"4325_CR27","doi-asserted-by":"crossref","first-page":"i103","DOI":"10.1136\/ard.59.suppl_1.i103","volume":"59","author":"MH Schiff","year":"2000","unstructured":"Schiff MH (2000) Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 59(suppl 1):i103\u2013i108","journal-title":"Ann Rheum Dis"},{"key":"4325_CR28","first-page":"1","volume-title":"In Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist","author":"WP Arend","year":"2001","unstructured":"Arend WP (2001) In Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Elsevier, Amsterdam, pp 1\u20136"},{"issue":"4","key":"4325_CR29","first-page":"484","volume":"20","author":"S Chang","year":"2004","unstructured":"Chang S, Wu J, Gong X (2004) Cloning of hIL-1Ra gene and its expression in E. coli. Xi bao yu fen zi mian yi xue za zhi Chin J Cell Mol Immunol 20(4):484\u2013487","journal-title":"Xi bao yu fen zi mian yi xue za zhi Chin J Cell Mol Immunol"},{"issue":"5","key":"4325_CR30","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1172\/JCI114622","volume":"85","author":"WP Arend","year":"1990","unstructured":"Arend WP, Welgus H, Thompson RC, Eisenberg S (1990) Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Investig 85(5):1694\u20131697","journal-title":"J Clin Investig"},{"issue":"2","key":"4325_CR31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780380202","volume":"38","author":"WP Arend","year":"1995","unstructured":"Arend WP, Dayer J-M (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthr Rheum 38(2):151\u2013160","journal-title":"Arthr Rheum"},{"issue":"12","key":"4325_CR32","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.1780331208","volume":"33","author":"P Seckinger","year":"1990","unstructured":"Seckinger P, Yaron I, Meyer FA, Yaron M, Dayer JM (1990) Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. Arthr Rheum 33(12):1807\u20131814","journal-title":"Arthr Rheum"},{"issue":"7","key":"4325_CR33","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","volume":"2","author":"T Huet","year":"2020","unstructured":"Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache J-M, B\u00e9zie Y, Laplanche S (2020) Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2(7):e393\u2013e400","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"4325_CR34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1165\/rcmb.2020-0277LE","volume":"63","author":"TL Hedrick","year":"2020","unstructured":"Hedrick TL, Murray BP, Hagan RS, Mock JR (2020) COVID-19: clean up on IL-6. Am J Respir Cell Mol Biol 63(4):541\u2013543","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"4325_CR35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8(9):1237","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4325_CR36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1681\/ASN.2014111147","volume":"27","author":"GS Braun","year":"2016","unstructured":"Braun GS, Nagayama Y, Maruta Y, Heymann F, van Roeyen CR, Klinkhammer BM, Boor P, Villa L, Salant DJ, Raffetseder U (2016) IL-6 trans-signaling drives murine crescentic GN. J Am Soc Nephrol 27(1):132\u2013142","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4325_CR37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50(4):1007\u20131023","journal-title":"Immunity"},{"issue":"12","key":"4325_CR38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ (2018) Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18(12):773\u2013789","journal-title":"Nat Rev Immunol"},{"key":"4325_CR39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","volume":"51","author":"A Saha","year":"2020","unstructured":"Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee S-S, Chakraborty C (2020) Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res 51:595","journal-title":"Arch Med Res"},{"issue":"16","key":"4325_CR40","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30(16):1443\u20131453","journal-title":"Mol Immunol"},{"issue":"1","key":"4325_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/cyto.1995.1003","volume":"7","author":"SA Siegel","year":"1995","unstructured":"Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE (1995) The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7(1):15\u201325","journal-title":"Cytokine"},{"issue":"2","key":"4325_CR42","first-page":"1","volume":"4","author":"RN Maini","year":"2002","unstructured":"Maini RN, Feldmann M (2002) How does Infliximab work in rheumatoid arthritis? Arthr Res Ther 4(2):1\u20137","journal-title":"Arthr Res Ther"},{"issue":"12","key":"4325_CR43","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1. Arthritis Rheum 36(12):1681\u20131690","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4325_CR44","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","volume":"43","author":"AK Ulfgren","year":"2000","unstructured":"Ulfgren AK, Andersson U, Engstr\u00f6m M, Klareskog L, Maini RN, Taylor PC (2000) Systemic anti\u2013tumor necrosis factor \u03b1 therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor \u03b1 synthesis. Arthr Rheum 43(11):2391\u20132396","journal-title":"Arthr Rheum"},{"issue":"3","key":"4325_CR45","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-\u03b1 therapy in rheumatoid arthritis. J Immunol 163(3):1521\u20131528","journal-title":"J Immunol"},{"issue":"2","key":"4325_CR46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.34172\/aim.2021.22","volume":"24","author":"M Farrokhpour","year":"2021","unstructured":"Farrokhpour M, Rezaie N, Moradi N, Rad FG, Izadi S, Azimi M, Zamani F, Izadi S, Ranjbar M, Makiani MJ (2021) Infliximab and intravenous Gammaglobulin in hospitalized severe COVID-19 patients in intensive care unit. Arch Iran Med 24(2):139\u2013143","journal-title":"Arch Iran Med"},{"key":"4325_CR47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","volume":"53","author":"F Coperchini","year":"2020","unstructured":"Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M (2020) The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine Growth Factor Rev 53:25\u201332","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10223","key":"4325_CR48","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (Lond, Engl) 395(10223):e30","journal-title":"Lancet (Lond, Engl)"},{"issue":"4","key":"4325_CR49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P (2020) COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 20(4):400\u2013402","journal-title":"Lancet Infect Dis"},{"key":"4325_CR50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","volume":"72","author":"BK Titanji","year":"2020","unstructured":"Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O\u2019Shea J, DeSilva K, Chan B, Edwards A (2020) Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis 72:1247","journal-title":"Clin Infect Dis"},{"key":"4325_CR51","unstructured":"World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) Situation Report\u2013145. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200613-covid-19-sitrep-145.pdf?sfvrsn=bb7c1dc9_2. Accessed 27 July 2021"},{"issue":"14","key":"4325_CR52","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00018-017-2520-2","volume":"74","author":"N Raftery","year":"2017","unstructured":"Raftery N, Stevenson NJ (2017) Advances in antiviral immune defence: revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci 74(14):2525\u20132535","journal-title":"Cell Mol Life Sci"},{"issue":"10229","key":"4325_CR53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Collaboration HAS (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (Lond, Engl) 395(10229):1033","journal-title":"Lancet (Lond, Engl)"},{"key":"4325_CR54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2020.03.065","volume":"159","author":"KS Cheung","year":"2020","unstructured":"Cheung KS, Hung IF, Chan PP, Lung K, Tso E, Liu R, Ng Y, Chu MY, Chung TW, Tam AR (2020) Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology 159:81","journal-title":"Gastroenterology"},{"issue":"5","key":"4325_CR55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1191\/1352458502ms826oa","volume":"8","author":"P Vermersch","year":"2002","unstructured":"Vermersch P, De Seze J, Delisse B, Lemaire S, Stojkovic T (2002) Quality of life in multiple sclerosis: influence of interferon-\u03b21a (Avonex\u00ae) treatment. Mult Scler J 8(5):377\u2013381","journal-title":"Mult Scler J"},{"key":"4325_CR56","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Florence A, Yazdanpanah Y, Mentre F, Lescure F-X, Peiffer-Smadja N (2020) Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 178:104791","journal-title":"Antiviral Res"},{"issue":"10","key":"4325_CR57","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1023\/A:1020468902694","volume":"19","author":"DE Mager","year":"2002","unstructured":"Mager DE, Jusko WJ (2002) Receptor-mediated pharmacokinetic\/pharmacodynamic model of interferon-\u03b2 1a in humans. Pharm Res 19(10):1537\u20131543","journal-title":"Pharm Res"},{"issue":"10234","key":"4325_CR58","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417\u20131418","journal-title":"Lancet"},{"issue":"24","key":"4325_CR59","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1056\/NEJMra1205750","volume":"367","author":"HK Eltzschig","year":"2012","unstructured":"Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367(24):2322\u20132333","journal-title":"N Engl J Med"},{"issue":"1","key":"4325_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jir.2007.0062","volume":"28","author":"T Laver","year":"2008","unstructured":"Laver T, Nozell SE, Benveniste EN (2008) IFN-\u03b2-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. J Interferon Cytokine Res 28(1):13\u201323","journal-title":"J Interferon Cytokine Res"},{"issue":"12","key":"4325_CR61","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1002\/eji.200737793","volume":"37","author":"J Kiss","year":"2007","unstructured":"Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M (2007) IFN-\u03b2 protects from vascular leakage via up-regulation of CD73. Eur J Immunol 37(12):3334\u20133338","journal-title":"Eur J Immunol"},{"key":"4325_CR62","first-page":"524","volume":"5","author":"J Jalkanen","year":"2020","unstructured":"Jalkanen J, Pettil\u00e4 V, Huttunen T, Hollm\u00e9n M, Jalkanen S (2020) Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intensiv Care Med 5:524","journal-title":"Intensiv Care Med"},{"issue":"1","key":"4325_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03048-5","volume":"24","author":"J Jalkanen","year":"2020","unstructured":"Jalkanen J, Hollm\u00e9n M, Jalkanen S (2020) Interferon beta-1a for COVID-19: critical importance of the administration route. Crit Care 24(1):1\u20133","journal-title":"Crit Care"},{"issue":"1","key":"4325_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02326-8","volume":"18","author":"S Tahamtan","year":"2020","unstructured":"Tahamtan S, Shirban F, Bagherniya M, Johnston TP, Sahebkar A (2020) The effects of statins on dental and oral health: a review of preclinical and clinical studies. J Transl Med 18(1):1\u201342","journal-title":"J Transl Med"},{"key":"4325_CR65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","volume":"6","author":"V Castiglione","year":"2020","unstructured":"Castiglione V, Chiriac\u00f2 M, Emdin M, Taddei S, Vergaro G (2020) Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother 6:258","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"4325_CR66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser R (2018) Immune modulatory effects of statins. Immunology 154(1):69\u201375","journal-title":"Immunology"},{"issue":"1","key":"4325_CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2014.02.091","volume":"446","author":"X Yuan","year":"2014","unstructured":"Yuan X, Deng Y, Guo X, Shang J, Zhu D, Liu H (2014) Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4\/MYD88 pathway. Biochem Biophys Res Commun 446(1):292\u2013297","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4325_CR68","first-page":"49","volume":"27","author":"P Chansrichavala","year":"2009","unstructured":"Chansrichavala P, Chantharaksri U, Sritara P, Chaiyaroj SC (2009) Atorvastatin attenuates TLR4-mediated NF-[kappa] B activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol 27(1):49","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"2","key":"4325_CR69","doi-asserted-by":"crossref","first-page":"e00398","DOI":"10.1128\/mBio.00398-20","volume":"11","author":"D Fedson","year":"2020","unstructured":"Fedson D, Opal S, Rordam O (2020) Treating patients with severe COVID-19 infection. MBio 11(2):e00398\u2013e00420","journal-title":"MBio"},{"issue":"S3","key":"4325_CR70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.4960261507","volume":"26","author":"JM McKenney","year":"2003","unstructured":"McKenney JM (2003) Pharmacologic characteristics of statins. Clin Cardiol 26(S3):32\u201338","journal-title":"Clin Cardiol"},{"issue":"3","key":"4325_CR71","first-page":"10.23812","volume":"34","author":"T Theoharides","year":"2020","unstructured":"Theoharides T, Conti P (2020) Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents 34(3):10.23812","journal-title":"J Biol Regul Homeost Agents"},{"issue":"3","key":"4325_CR72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41591-020-0796-5","volume":"26","author":"LL Poon","year":"2020","unstructured":"Poon LL, Peiris M (2020) Emergence of a novel human coronavirus threatening human health. Nat Med 26(3):317\u2013319","journal-title":"Nat Med"},{"issue":"5","key":"4325_CR73","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig 130(5):2620","journal-title":"J Clin Investig"},{"issue":"1","key":"4325_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson M-KN, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6(1):1\u201313","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4325_CR75","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","volume":"13","author":"H Chen","year":"2019","unstructured":"Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B (2019) Management of cytokine release syndrome related to CAR-T cell therapy. Front Med 13(5):610\u2013617","journal-title":"Front Med"},{"key":"4325_CR76","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S (2020) Remdesivir for the treatment of Covid-19\u2014preliminary report. N Engl J Med 383:1813","journal-title":"N Engl J Med"},{"key":"4325_CR77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20:355","journal-title":"Nat Rev Immunol"},{"key":"4325_CR78","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/biof.1633","volume":"46","author":"TC Theoharides","year":"2020","unstructured":"Theoharides TC (2020) COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors (Oxf, Engl) 46:306","journal-title":"Biofactors (Oxf, Engl)"},{"key":"4325_CR79","doi-asserted-by":"crossref","first-page":"101942","DOI":"10.1016\/j.pupt.2020.101942","volume":"63","author":"RB Hogan II","year":"2020","unstructured":"Hogan RB II, Hogan RB III, Cannon T, Rappai M, Studdard J, Paul D, Dooley TP (2020) Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther 63:101942","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"4325_CR80","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5114\/aoms.2012.27295","volume":"8","author":"T Kmiecik","year":"2012","unstructured":"Kmiecik T, Otocka-Kmiecik A, G\u00f3rska-Ciebiada M, Ciebiada M (2012) T lymphocytes as a target of histamine action. Arch Med Sci AMS 8(1):154","journal-title":"Arch Med Sci AMS"},{"key":"4325_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9524075","volume":"2018","author":"ACCC Branco","year":"2018","unstructured":"Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN (2018) Role of histamine in modulating the immune response and inflammation. Mediat Inflamm 2018:1\u201310","journal-title":"Mediat Inflamm"},{"issue":"6","key":"4325_CR82","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/j.jvca.2011.02.005","volume":"25","author":"MM Maddali","year":"2011","unstructured":"Maddali MM, Mathew M, Chandwani J, Alsajwani MJ, Ganguly SS (2011) Outcomes after rigid bronchoscopy in children with suspected or confirmed foreign body aspiration: a retrospective study. J Cardiothorac Vasc Anesth 25(6):1005\u20131008","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"4325_CR83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003495-199040010-00006","volume":"40","author":"PA Todd","year":"1990","unstructured":"Todd PA, Clissold SP (1990) Naproxen. Drugs 40(1):91\u2013137","journal-title":"Drugs"},{"key":"4325_CR84","unstructured":"American Society of Health-System Pharmacists (ASHP) (2021) Naproxen. https:\/\/www.drugs.com\/monograph\/naproxen.html. Accessed 11 Aug 2021"},{"key":"4325_CR85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/DDDT.S8410","volume":"4","author":"CK Khoury","year":"2010","unstructured":"Khoury CK, Couch JR (2010) Sumatriptan-Naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des Dev Ther 4:9","journal-title":"Drug Des Dev Ther"},{"issue":"45","key":"4325_CR86","doi-asserted-by":"crossref","first-page":"34950","DOI":"10.1074\/jbc.M110.162982","volume":"285","author":"KC Duggan","year":"2010","unstructured":"Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, Marnett LJ (2010) Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem 285(45):34950\u201334959","journal-title":"J Biol Chem"},{"issue":"7","key":"4325_CR87","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.842","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Charlesworth A, Van Ganse E, LeParc JM, Jones JK, Wall R, Schneid H, Verriere F (2003) Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf 12(7):601\u2013610","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4325_CR88","first-page":"341","volume-title":"In Colchicine\u2014update on mechanisms of action and therapeutic uses","author":"YY Leung","year":"2015","unstructured":"Leung YY, Hui LLY, Kraus VB (2015) In Colchicine\u2014update on mechanisms of action and therapeutic uses. Elsevier, Amsterdam, pp 341\u2013350"},{"issue":"3","key":"4325_CR89","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","volume":"10","author":"G Nuki","year":"2008","unstructured":"Nuki G (2008) Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 10(3):218\u2013227","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"4325_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780130101","volume":"13","author":"P Phelps","year":"1970","unstructured":"Phelps P (1970) Polymorphonuclear leukocyte motility in vitro. IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthr Rheum 13(1):1\u20139","journal-title":"Arthr Rheum"},{"issue":"9","key":"4325_CR91","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2005-03-1161","volume":"106","author":"N Mizumoto","year":"2005","unstructured":"Mizumoto N, Gao J, Matsushima H, Ogawa Y, Tanaka H, Takashima A (2005) Discovery of novel immunostimulants by dendritic-cell\u2013based functional screening. Blood 106(9):3082\u20133089","journal-title":"Blood"},{"issue":"6","key":"4325_CR92","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.jid.5700699","volume":"127","author":"N Mizumoto","year":"2007","unstructured":"Mizumoto N, Tanaka H, Matsushima H, Vishwanath M, Takashima A (2007) Colchicine promotes antigen cross-presentation by murine dendritic cells. J Investig Dermatol 127(6):1543\u20131546","journal-title":"J Investig Dermatol"},{"issue":"4","key":"4325_CR93","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CJI.0b013e3181cd1094","volume":"33","author":"V Marin-Esteban","year":"2010","unstructured":"Marin-Esteban V, Charron D, Gelin C, Mooney N (2010) Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. J Immunother 33(4):364\u2013370","journal-title":"J Immunother"},{"issue":"6","key":"4325_CR94","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mlc.2002.124397","volume":"139","author":"C Li","year":"2002","unstructured":"Li C, Yang CW, Ahn HJ, Kim WY, Park CW, Park JH, Lee MJ, Yang JH, Kim Y-S, Bang BK (2002) Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity. J Lab Clin Med 139(6):364\u2013371","journal-title":"J Lab Clin Med"},{"issue":"22","key":"4325_CR95","doi-asserted-by":"crossref","first-page":"15466","DOI":"10.1074\/jbc.M113.464461","volume":"288","author":"N Sandbo","year":"2013","unstructured":"Sandbo N, Ngam C, Torr E, Kregel S, Kach J, Dulin N (2013) Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2. J Biol Chem 288(22):15466\u201315473","journal-title":"J Biol Chem"},{"issue":"4","key":"4325_CR96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40495-020-00225-6","volume":"6","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Firestein BL, Brunetti L (2020) Colchicine in COVID-19: an old drug, new use. Curr Pharmacol Rep 6(4):137\u2013145","journal-title":"Curr Pharmacol Rep"},{"key":"4325_CR97","first-page":"1","volume":"30","author":"J-C Tardif","year":"2021","unstructured":"Tardif J-C, Bouabdallaoui N, L\u2019Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S (2021) Efficacy of colchicine in non-hospitalized patients with COVID-19. Medrxiv 30:1","journal-title":"Medrxiv"},{"key":"4325_CR98","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10067-020-05144-x","volume":"39","author":"M Cumhur Cure","year":"2020","unstructured":"Cumhur Cure M, Kucuk A, Cure E (2020) Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol 39:2101\u20132102","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4325_CR99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/brainsci9100285","volume":"9","author":"JG Lee","year":"2019","unstructured":"Lee JG, Woo YS, Park SW, Seog D-H, Seo MK, Bahk W-M (2019) The neuroprotective effects of Melatonin: possible role in the pathophysiology of neuropsychiatric disease. Brain Sci 9(10):285","journal-title":"Brain Sci"},{"issue":"1","key":"4325_CR100","first-page":"1000151","volume":"4","author":"A Masters","year":"2014","unstructured":"Masters A, Pandi-Perumal SR, Seixas A, Girardin J-L, McFarlane SI (2014) Melatonin, the hormone of darkness: from sleep promotion to ebola treatment. Brain Disord Ther 4(1):1000151","journal-title":"Brain Disord Ther"},{"key":"4325_CR101","unstructured":"Auld F, Maschauer E, Morrison I, Skene D, Riha R, Riha RL (2016) Sincere thanks to Lisa Wood and Tomas Ray for assistance with editing. Conflicts of interest\u2013None"},{"issue":"2","key":"4325_CR102","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-079X.2009.00700.x","volume":"47","author":"M Carretero","year":"2009","unstructured":"Carretero M, Escames G, L\u00f3pez LC, Venegas C, Dayoub JC, Garcia L, Acu\u00f1a-Castroviejo D (2009) Long-term melatonin administration protects brain mitochondria from aging. J Pineal Res 47(2):192\u2013200","journal-title":"J Pineal Res"},{"key":"4325_CR103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fendo.2019.00249","volume":"10","author":"D Zhao","year":"2019","unstructured":"Zhao D, Yu Y, Shen Y, Liu Q, Zhao Z, Sharma R, Reiter RJ (2019) Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol 10:249","journal-title":"Front Endocrinol"},{"issue":"1","key":"4325_CR104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/jcem-55-1-27","volume":"55","author":"H Iguchi","year":"1982","unstructured":"Iguchi H, Kato K-I, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55(1):27\u201329","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4325_CR105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1517\/13543784.10.3.467","volume":"10","author":"GJ Maestroni","year":"2001","unstructured":"Maestroni GJ (2001) The immunotherapeutic potential of Melatonin. Expert Opin Investig Drugs 10(3):467\u2013476","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"4325_CR106","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4049\/jimmunol.159.2.574","volume":"159","author":"S Garcia-Maurino","year":"1997","unstructured":"Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, Guerrero JM (1997) Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 159(2):574\u2013581","journal-title":"J Immunol"},{"issue":"3","key":"4325_CR107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001432-200206000-00008","volume":"15","author":"N Grandvaux","year":"2002","unstructured":"Grandvaux N, Servant MJ, Hiscott J (2002) The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 15(3):259\u2013267","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"4325_CR108","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/v10080392","volume":"10","author":"OA Khomich","year":"2018","unstructured":"Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV (2018) Redox biology of respiratory viral infections. Viruses 10(8):392","journal-title":"Viruses"},{"issue":"11","key":"4325_CR109","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1084\/jem.20150632","volume":"212","author":"R Vijay","year":"2015","unstructured":"Vijay R, Hua X, Meyerholz DK, Miki Y, Yamamoto K, Gelb M, Murakami M, Perlman S (2015) Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome\u2013CoV infection. J Exp Med 212(11):1851\u20131868","journal-title":"J Exp Med"},{"issue":"1","key":"4325_CR110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-079X.2006.00407.x","volume":"42","author":"DX Tan","year":"2007","unstructured":"Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007) One molecule, many derivatives: a never-ending interaction of Melatonin with reactive oxygen and nitrogen species? J Pineal Res 42(1):28\u201342","journal-title":"J Pineal Res"},{"issue":"4","key":"4325_CR111","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000164122","volume":"65","author":"C Constantinescu","year":"1997","unstructured":"Constantinescu C, Hilliard B, Ventura E, Rostami A (1997) Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 65(4):190\u2013194","journal-title":"Pathobiology"},{"issue":"9","key":"4325_CR112","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/nu12092561","volume":"12","author":"K Kleszczy\u0144ski","year":"2020","unstructured":"Kleszczy\u0144ski K, Slominski AT, Steinbrink K, Reiter RJ (2020) Clinical trials for use of melatonin to fight against COVID-19 are urgently needed. Nutrients 12(9):2561","journal-title":"Nutrients"},{"key":"4325_CR113","doi-asserted-by":"crossref","first-page":"e15750","DOI":"10.1200\/JCO.2016.34.15_suppl.e15750","volume":"34","author":"A Whiteley","year":"2016","unstructured":"Whiteley A, Becerra C, McCollum D, Paulson AS, Goel A (2016) A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients. Am Soc Clin Oncol 34:e15750","journal-title":"Am Soc Clin Oncol"},{"key":"4325_CR114","first-page":"32","volume":"1580","author":"M Alpa","year":"2015","unstructured":"Alpa M (2015) Anakinra\/colchicine. Reactions 1580:32\u201335","journal-title":"Reactions"},{"issue":"1","key":"4325_CR115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","volume":"74","author":"BB Yang","year":"2003","unstructured":"Yang BB, Baughman S, Sullivan JT (2003) Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 74(1):85\u201394","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4325_CR116","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"M Mertens","year":"2009","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36(6):1118\u20131125","journal-title":"J Rheumatol"},{"issue":"7","key":"4325_CR117","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2665-9913(20)30160-0","volume":"2","author":"A King","year":"2020","unstructured":"King A, Vail A, O\u2019Leary C, Hannan C, Brough D, Patel H, Galea J, Ogungbenro K, Wright M, Pathmanaban O (2020) Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol 2(7):e379\u2013e381","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"4325_CR118","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.reumae.2020.04.012","volume":"17","author":"A Mu\u00f1oz-Jim\u00e9nez","year":"2021","unstructured":"Mu\u00f1oz-Jim\u00e9nez A, Rubio-Romero E, de la Fuente JLM (2021) Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19. Reumatol Cl\u00edn (English Edit) 17(6):309\u2013312","journal-title":"Reumatol Cl\u00edn (English Edit)"},{"issue":"5","key":"4325_CR119","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3899\/jrheum.121098","volume":"40","author":"PJ Kahn","year":"2013","unstructured":"Kahn PJ, Cron RQ (2013) Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 40(5):743\u2013744","journal-title":"J Rheumatol"},{"key":"4325_CR120","doi-asserted-by":"crossref","first-page":"198070","DOI":"10.1016\/j.virusres.2020.198070","volume":"286","author":"G Magro","year":"2020","unstructured":"Magro G (2020) COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res 286:198070","journal-title":"Virus Res"},{"issue":"23","key":"4325_CR121","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","volume":"585","author":"T Tanaka","year":"2011","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2011) Anti-interleukin-6 receptor antibody, Tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585(23):3699\u20133709","journal-title":"FEBS Lett"},{"key":"4325_CR122","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"R Keizer","year":"2010","unstructured":"Keizer R, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493\u2013507","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4325_CR123","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/eci.10.70","volume":"6","author":"T Tanaka","year":"2010","unstructured":"Tanaka T, Ogata A, Narazaki M (2010) Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 6(6):843\u2013854","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"4325_CR124","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","volume":"57","author":"H Abdallah","year":"2017","unstructured":"Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A (2017) Pharmacokinetic and pharmacodynamic analysis of subcutaneous Tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol 57(4):459\u2013468","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4325_CR125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00296-009-1292-x","volume":"31","author":"V Connor","year":"2011","unstructured":"Connor V (2011) Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int 31(3):327\u2013337","journal-title":"Rheumatol Int"},{"issue":"12","key":"4325_CR126","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.dld.2013.06.007","volume":"45","author":"LR Lopetuso","year":"2013","unstructured":"Lopetuso LR, Petito V, Cufino V, Arena V, Stigliano E, Gerardi V, Gaetani E, Poscia A, Amato A, Cammarota G (2013) Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. Dig Liver Dis 45(12):1017\u20131021","journal-title":"Dig Liver Dis"},{"issue":"4","key":"4325_CR127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4291\/wjgp.v6.i4.219","volume":"6","author":"H Akiho","year":"2015","unstructured":"Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H (2015) Promising biological therapies for ulcerative colitis: a review of the literature. World J Gastrointest Pathophysiol 6(4):219","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"12","key":"4325_CR128","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor \u03b1 inhibitor infliximab. Arthr Rheum 54(12):3782\u20133789","journal-title":"Arthr Rheum"},{"key":"4325_CR129","unstructured":"Bethesda (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548012\/. Accessed 10 Nov 2021"},{"issue":"3","key":"4325_CR130","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2021","unstructured":"Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B (2021) The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol 147(3):814\u2013826","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4325_CR131","first-page":"34","volume":"42","author":"E Lilly","year":"2019","unstructured":"Lilly E (2019) Baricitinib for rheumatoid arthritis. Aust Prescr 42(1):34\u201335","journal-title":"Aust Prescr"},{"key":"4325_CR132","unstructured":"National Center for Biotechnology Information (2021) PubChem Compound Summary for CID 44205240, Baricitinib. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Baricitinib. Accessed 10 Nov 2021"},{"key":"4325_CR133","first-page":"106","volume":"1611","author":"S De Massougnes","year":"2016","unstructured":"De Massougnes S (2016) Interferon-\u03b2-1a. Reactions 1611:106\u2013123","journal-title":"Reactions"},{"issue":"10","key":"4325_CR134","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/10799900050163226","volume":"20","author":"P-A Buchwalder","year":"2000","unstructured":"Buchwalder P-A, Buclin T, Trinchard I, Munafo A, Biollaz J (2000) Pharmacokinetics and pharmacodynamics of IFN-\u03b21a in healthy volunteers. J Interferon Cytokine Res 20(10):857\u2013866","journal-title":"J Interferon Cytokine Res"},{"key":"4325_CR135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3\u201311","journal-title":"Pharmacol Res"},{"issue":"4","key":"4325_CR136","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1208\/s12249-011-9673-3","volume":"12","author":"FN Khan","year":"2011","unstructured":"Khan FN, Dehghan MHG (2011) Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. AAPS PharmSciTech 12(4):1077\u20131086","journal-title":"AAPS PharmSciTech"},{"issue":"13","key":"4325_CR137","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","volume":"42","author":"H Lennern\u00e4s","year":"2003","unstructured":"Lennern\u00e4s H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42(13):1141\u20131160","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"4325_CR138","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41415-020-2238-7","volume":"229","author":"S Morganstein","year":"2020","unstructured":"Morganstein S, Morganstein D, Morganstein L (2020) Dexamethasone caution. Br Dent J 229(7):398\u2013398","journal-title":"Br Dent J"},{"issue":"4","key":"4325_CR139","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0960-0760(97)00038-1","volume":"62","author":"E Tomlinson","year":"1997","unstructured":"Tomlinson E, Maggs J, Park B, Back D (1997) Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol 62(4):345\u2013352","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"4325_CR140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-13-141","volume":"13","author":"J Cronin","year":"2012","unstructured":"Cronin J, Kennedy U, McCoy S, an Fhail\u00ed SN, Crispino-O\u2019Connell G, Hayden J, Wakai A, Walsh S, O\u2019Sullivan R (2012) Single dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial. Trials 13(1):1\u201311","journal-title":"Trials"},{"issue":"1","key":"4325_CR141","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12295","volume":"78","author":"SM Spoorenberg","year":"2014","unstructured":"Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn G, Rijkers GT, Bos WJW, van de Garde EM (2014) Pharmacokinetics of oral vs. intravenous Dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol 78(1):78\u201383","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4325_CR142","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.otc.2018.05.004","volume":"51","author":"DR Cox","year":"2018","unstructured":"Cox DR, Wise SK (2018) Medical treatment of nasal airway obstruction. Otolaryngol Clin North Am 51(5):897\u2013908","journal-title":"Otolaryngol Clin North Am"},{"key":"4325_CR143","unstructured":"Nguyen K, Dersnah GD, Ahlawat R (2020) Famotidine. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island"},{"issue":"3","key":"4325_CR144","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2165\/00003088-199121030-00003","volume":"21","author":"H Echizen","year":"1991","unstructured":"Echizen H, Ishizaki T (1991) Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 21(3):178\u2013194","journal-title":"Clin Pharmacokinet"},{"key":"4325_CR145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004836-198707002-00003","volume":"9","author":"A Chremos","year":"1987","unstructured":"Chremos A (1987) Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol 9:7\u201312","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"4325_CR146","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.107.122283","volume":"322","author":"ML Capone","year":"2007","unstructured":"Capone ML, Tacconelli S, Sciulli MG, Anzellotti P, Di Francesco L, Merciaro G, Di Gregorio P, Patrignani P (2007) Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322(2):453\u2013460","journal-title":"J Pharmacol Exp Ther"},{"issue":"4 Suppl","key":"4325_CR147","first-page":"222","volume":"25","author":"E Segre","year":"1980","unstructured":"Segre E (1980) Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions. J Reprod Med 25(4 Suppl):222\u2013225","journal-title":"J Reprod Med"},{"issue":"1\u20133","key":"4325_CR148","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-5173(87)90106-2","volume":"38","author":"M Calvo","year":"1987","unstructured":"Calvo M, Lanao J, Dominguez-Gil A (1987) Bioavailability of rectally administered Naproxen. Int J Pharm 38(1\u20133):117\u2013122","journal-title":"Int J Pharm"},{"issue":"4","key":"4325_CR149","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00194404","volume":"46","author":"M Rochdi","year":"1994","unstructured":"Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann J (1994) Pharmacokinetics and absolute bioavailability of Colchicine after iv and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 46(4):351\u2013354","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4325_CR150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000018407","volume":"200","author":"M Grimaitre","year":"2000","unstructured":"Grimaitre M, Etienne A, Fathi M, Piletta P-A, Saurat J-H (2000) Topical colchicine therapy for actinic keratoses. Dermatology 200(4):346\u2013348","journal-title":"Dermatology"},{"key":"4325_CR151","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.2147\/DDDT.S140574","volume":"11","author":"S Lev","year":"2017","unstructured":"Lev S, Snyder D, Azran C, Zolotarsky V, Dahan A (2017) Severe hypertriglyceridemia and Colchicine intoxication following suicide attempt. Drug Des Dev Ther 11:3321","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"4325_CR152","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0248-8663(96)80790-9","volume":"16","author":"O Chappey","year":"1995","unstructured":"Chappey O, Scherrmann J (1995) Colchicine: recent data on pharmacokinetics and clinical pharmacology. Rev Med Interne 16(10):782\u2013789","journal-title":"Rev Med Interne"},{"issue":"5","key":"4325_CR153","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","volume":"48","author":"Y Finkelstein","year":"2010","unstructured":"Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 48(5):407\u2013414","journal-title":"Clin Toxicol"},{"key":"4325_CR154","unstructured":"Bauer B (2017) Melatonin side effects: what are the risks. Mayo Clin 10"},{"key":"4325_CR155","unstructured":"Zetner DB, Andersen LPK, Rosenberg J. Pharmacokinetics of intravenous, rectal, intravesical, vaginal, and transdermal administration of exogenous Melatonin in healthy female volunteers: a crossover study"},{"issue":"3","key":"4325_CR156","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/1570159X14666161228122115","volume":"15","author":"S Tordjman","year":"2017","unstructured":"Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C (2017) Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol 15(3):434\u2013443","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"4325_CR157","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/00912700022009422","volume":"40","author":"RL DeMuro","year":"2000","unstructured":"DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40(7):781\u2013784","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4325_CR158","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-079X.2011.00958.x","volume":"52","author":"NS Gooneratne","year":"2012","unstructured":"Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS (2012) Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res 52(4):437\u2013445","journal-title":"J Pineal Res"},{"key":"4325_CR159","volume-title":"COVID-19 evolution during the pandemic\u2013implications of new SARS-CoV-2 variants on disease control and public health policies","author":"C van Oosterhout","year":"2021","unstructured":"van Oosterhout C, Hall N, Ly H, Tyler KM (2021) COVID-19 evolution during the pandemic\u2013implications of new SARS-CoV-2 variants on disease control and public health policies. Taylor & Francis, Routledge"},{"issue":"7","key":"4325_CR160","doi-asserted-by":"crossref","first-page":"102566","DOI":"10.1016\/j.autrev.2020.102566","volume":"19","author":"O Gendelman","year":"2020","unstructured":"Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G (2020) Continuous Hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis. Autoimmun Rev 19(7):102566","journal-title":"Autoimmun Rev"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-021-04325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-021-04325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-021-04325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T09:09:37Z","timestamp":1674378577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-021-04325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4325"],"URL":"https:\/\/doi.org\/10.1007\/s11010-021-04325-9","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}